Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Leases (Tables)

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Financing and Operating Leases

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

	Classification on the Balance Sheet	March 31, 2020
		(unaudited)
Assets
Financing lease assets	Property and equipment, net	$	475
Operating lease assets	Operating lease right of use assets		2,811
Total lease assets		$	3,286

Liabilities
Current
Financing lease liabilities	Other accrued expenses	$	160
Operating lease liabilities	Other accrued expenses		1,251
Total current lease liabilities		$	1,411
Noncurrent
Financing lease liabilities	Other long-term liabilities		85
Operating lease liabilities	Operating lease liabilities, net of current portion		1,384
Total long-term lease liabilities			1,469
Total lease liabilities		$	2,880

Schedule of Maturities of Operating and Financing Lease Liabilities

The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of March 31, 2020:

	Operating Leases		Financing Leases
2020		1,189		170
2021		878		120
2022		660		13
2023		250		-
Total minimum lease payments		2,977		303
Less: amount of lease payments representing effects of discounting		342		58
Present value of future minimum lease payments		2,635		245
Less: current obligations under leases		1,251		160
Long-term lease obligations	$	1,384	$	85

Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases

As of March 31, 2020, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows:

			Less than		1 to 3		3 to 5		After
	Total		1 Year		Years		Years		5 Years
Operating lease obligations	$	2,977	$	1,189	$	1,538	$	250	$	-